MeSH term
Frequency | Condition_Probility | Genetic Markers | 4 | 0.0 |
Genotype | 55 | 0.0 |
HLA-DQ Antigens/genetics | 23 | 8.0 |
HLA-DR Antigens/genetics | 14 | 3.0 |
Histocompatibility Testing/methods | 2 | 4.0 |
Humans | 190 | 0.0 |
Research Support, Non-U.S. Gov't | 129 | 0.0 |
Risk Assessment | 4 | 0.0 |
ATP-Binding Cassette Transporters/*genetics | 3 | 1.0 |
Adolescent | 42 | 0.0 |
Adult | 61 | 0.0 |
Aged | 27 | 0.0 |
Alleles | 90 | 1.0 |
Child | 41 | 0.0 |
Female | 92 | 0.0 |
Genetic Predisposition to Disease | 24 | 1.0 |
HLA-DQ Antigens/*genetics | 89 | 23.0 |
HLA-DR Antigens/*genetics | 24 | 4.0 |
Histocompatibility Testing | 21 | 2.0 |
Linkage Disequilibrium | 10 | 1.0 |
Major Histocompatibility Complex/genetics | 2 | 3.0 |
Male | 82 | 0.0 |
Middle Aged | 38 | 0.0 |
*Polymorphism, Genetic | 21 | 0.0 |
Age Factors | 6 | 0.0 |
Child, Preschool | 28 | 0.0 |
Gene Frequency | 34 | 0.0 |
Haplotypes | 33 | 1.0 |
Homozygote | 10 | 0.0 |
Infant | 16 | 0.0 |
Phenotype | 14 | 0.0 |
Sex Factors | 2 | 0.0 |
Case-Control Studies | 17 | 0.0 |
DNA/genetics | 7 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Odds Ratio | 5 | 0.0 |
Polymerase Chain Reaction | 39 | 0.0 |
Polymorphism, Genetic | 16 | 0.0 |
Taiwan | 2 | 1.0 |
Asian Continental Ancestry Group/*genetics | 5 | 1.0 |
China/ethnology | 3 | 1.0 |
English Abstract | 14 | 0.0 |
Linkage (Genetics) | 6 | 0.0 |
Autoantigens/*immunology | 2 | 1.0 |
Cohort Studies | 7 | 0.0 |
DNA/analysis | 4 | 0.0 |
HLA-DQ Antigens/blood/*genetics | 2 | 66.0 |
Polymorphism, Genetic/*genetics | 6 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Ethnic Groups | 2 | 0.0 |
Prevalence | 2 | 0.0 |
Base Sequence | 40 | 0.0 |
Comparative Study | 26 | 0.0 |
DNA Primers | 8 | 0.0 |
Family | 4 | 1.0 |
France/epidemiology | 2 | 1.0 |
HLA-DQ Antigens/*blood/genetics | 2 | 100.0 |
*Immunoconjugates | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 20 | 0.0 |
Reference Values | 7 | 0.0 |
Risk Factors | 19 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 40 | 0.0 |
Biological Markers | 3 | 0.0 |
Probability | 2 | 0.0 |
Registries | 4 | 1.0 |
Sensitivity and Specificity | 7 | 0.0 |
Autoantibodies/*blood | 6 | 2.0 |
*Genetic Predisposition to Disease | 12 | 1.0 |
Glutamate Decarboxylase/immunology | 9 | 31.0 |
Infant, Newborn | 10 | 0.0 |
Insulin/immunology | 2 | 15.0 |
Islets of Langerhans/*immunology | 6 | 17.0 |
Isoenzymes/immunology | 2 | 15.0 |
Lymphotoxin/genetics | 4 | 6.0 |
Major Histocompatibility Complex | 3 | 1.0 |
Microsatellite Repeats | 5 | 0.0 |
Pedigree | 6 | 0.0 |
Tumor Necrosis Factor-alpha/genetics | 6 | 2.0 |
*Alleles | 18 | 1.0 |
*Gene Frequency | 3 | 0.0 |
HLA Antigens/*genetics | 5 | 0.0 |
*Linkage Disequilibrium | 4 | 2.0 |
Tunisia | 2 | 4.0 |
Asthma/*genetics | 2 | 3.0 |
Family Health | 2 | 0.0 |
Amino Acid Sequence | 10 | 0.0 |
Autoantibodies/*immunology | 2 | 0.0 |
DNA Topoisomerases, Type I/*immunology | 3 | 50.0 |
*Genes, MHC Class II | 7 | 2.0 |
Molecular Sequence Data | 40 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Pregnancy | 9 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Antigens, Differentiation/*genetics | 2 | 1.0 |
Arthritis, Rheumatoid/*genetics | 2 | 2.0 |
Tumor Necrosis Factor-alpha/*genetics | 4 | 1.0 |
Autoantibodies/blood | 7 | 4.0 |
Prospective Studies | 6 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Survival Analysis | 2 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Diabetes Mellitus, Type 1/*genetics | 18 | 8.0 |
Glutamate Decarboxylase/*immunology | 2 | 10.0 |
Heterozygote | 7 | 0.0 |
Parents | 2 | 2.0 |
Autoantibodies/analysis | 2 | 1.0 |
Glucose Tolerance Test | 2 | 0.0 |
Logistic Models | 3 | 0.0 |
Immunoglobulin A/blood | 4 | 3.0 |
Nuclear Family | 6 | 2.0 |
Epitopes/genetics | 2 | 2.0 |
Haplotypes/genetics | 5 | 0.0 |
Microsatellite Repeats/*genetics | 2 | 0.0 |
Immunosuppressive Agents/therapeutic use | 2 | 0.0 |
Autoimmunity/*genetics | 2 | 14.0 |
Cell Line | 9 | 0.0 |
Spain | 2 | 0.0 |
Animals | 10 | 0.0 |
China | 4 | 0.0 |
Chromosome Mapping | 8 | 0.0 |
Confidence Intervals | 2 | 0.0 |
Diabetes Mellitus, Type 1/*genetics/*immunology | 5 | 22.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Great Britain | 3 | 1.0 |
HLA-DP Antigens/*genetics | 7 | 8.0 |
Italy | 4 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Diabetes Mellitus, Type 1/*epidemiology/*genetics/immunology | 3 | 100.0 |
Finland/epidemiology | 5 | 4.0 |
Follow-Up Studies | 4 | 0.0 |
*Genetic Screening | 2 | 1.0 |
Incidence | 5 | 0.0 |
Islets of Langerhans/immunology | 5 | 13.0 |
Longitudinal Studies | 2 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Time Factors | 5 | 0.0 |
Germany | 2 | 0.0 |
HLA-DP Antigens/genetics | 7 | 14.0 |
HLA-DR4 Antigen/*genetics | 2 | 6.0 |
European Continental Ancestry Group/genetics | 4 | 0.0 |
Genes, MHC Class II | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
Microsatellite Repeats/genetics | 2 | 0.0 |
*Polymerase Chain Reaction | 5 | 2.0 |
Forensic Medicine | 2 | 3.0 |
*Polymorphism, Single-Stranded Conformational | 4 | 3.0 |
*Genotype | 4 | 1.0 |
Age of Onset | 2 | 0.0 |
Diabetes Mellitus, Type 1/genetics/*immunology | 4 | 8.0 |
Immunoglobulin G/blood | 3 | 1.0 |
*Lymphocyte Activation | 2 | 0.0 |
T-Lymphocytes/*immunology | 2 | 0.0 |
HLA Antigens/genetics/immunology | 2 | 6.0 |
*Histocompatibility Testing | 3 | 1.0 |
Risk | 2 | 0.0 |
Transplantation, Homologous | 3 | 0.0 |
Exons/genetics | 2 | 0.0 |
Histocompatibility Testing/*methods | 6 | 3.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Diabetes Mellitus, Type 2/*genetics | 2 | 1.0 |
Codon | 2 | 0.0 |
HLA-DQ Antigens/classification/*genetics | 2 | 13.0 |
Histocompatibility Antigens Class II/*genetics | 8 | 4.0 |
*Microsatellite Repeats | 2 | 0.0 |
C-Peptide/blood | 3 | 1.0 |
Finland | 2 | 0.0 |
African Continental Ancestry Group/*genetics | 3 | 1.0 |
European Continental Ancestry Group/*genetics | 4 | 1.0 |
*HIV-1 | 2 | 0.0 |
HLA-DQ Antigens/*classification/genetics | 2 | 50.0 |
HLA-D Antigens/*genetics | 4 | 2.0 |
European Continental Ancestry Group | 4 | 0.0 |
Genes, MHC Class II/*genetics | 3 | 4.0 |
Evolution, Molecular | 2 | 0.0 |
Polymorphism, Genetic/genetics | 4 | 0.0 |
Sequence Alignment | 5 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Autoimmune Diseases/*genetics | 2 | 4.0 |
Random Allocation | 3 | 0.0 |
HLA-DQ Antigens/biosynthesis/*genetics | 2 | 50.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Disease Progression | 4 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Brazil | 2 | 0.0 |
*Evolution | 2 | 1.0 |
DNA, Complementary | 2 | 0.0 |
Mice | 4 | 0.0 |
Phylogeny | 3 | 0.0 |
Chi-Square Distribution | 3 | 0.0 |
Japan | 4 | 0.0 |
Disease Susceptibility | 4 | 0.0 |
HLA-DQ Antigens/analysis/*genetics | 3 | 30.0 |
Histocompatibility Antigens Class I/*genetics | 6 | 1.0 |
Antibody Formation | 2 | 0.0 |
Cattle | 3 | 0.0 |
Regression Analysis | 3 | 0.0 |
HLA-DQ Antigens/genetics/immunology | 3 | 15.0 |
HLA-DQ Antigens/genetics/*immunology | 4 | 30.0 |
*Mutation | 2 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Prognosis | 3 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 2 | 0.0 |
Tissue Donors | 2 | 0.0 |
HLA-DQ Antigens/*analysis | 2 | 11.0 |
Bone Marrow Transplantation/*immunology | 3 | 2.0 |
Diabetes Mellitus, Type 1/epidemiology/*genetics/*immunology | 2 | 22.0 |
Disease Susceptibility/immunology | 3 | 4.0 |
Severity of Illness Index | 2 | 0.0 |
HLA-DQ Antigens/*analysis/genetics | 2 | 12.0 |
*Software | 2 | 3.0 |
Genetics, Population | 3 | 0.0 |
Polymerase Chain Reaction/*methods | 5 | 0.0 |
Aspartic Acid | 2 | 4.0 |
Autoimmunity | 2 | 1.0 |
Cell Line, Transformed | 3 | 0.0 |
Aspartic Acid/*genetics | 2 | 15.0 |
Reproducibility of Results | 2 | 0.0 |
Histocompatibility Antigens Class II/genetics | 4 | 3.0 |
Protein Binding | 2 | 0.0 |
T-Lymphocytes | 2 | 0.0 |
United States | 2 | 0.0 |
HLA-DQ Antigens/*genetics/metabolism | 2 | 66.0 |
HLA-B Antigens/*genetics | 2 | 0.0 |
DNA/*genetics | 2 | 0.0 |
Immunophenotyping | 2 | 0.0 |
Geography | 2 | 3.0 |
HLA-DR Antigens/genetics/*immunology | 2 | 6.0 |
Oligonucleotide Probes | 4 | 0.0 |
*ATP-Binding Cassette Transporters | 2 | 1.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Russia | 2 | 2.0 |
Scleroderma, Systemic/genetics/*immunology | 2 | 28.0 |
Centromere/*immunology | 2 | 100.0 |
Insulin/*genetics | 2 | 3.0 |
*Oligonucleotide Probes | 2 | 8.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 2 | 3.0 |
Blotting, Southern | 4 | 0.0 |
DNA | 3 | 0.0 |
Autoantibodies/*analysis | 2 | 0.0 |
Scleroderma, Systemic/*immunology | 2 | 7.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Gene Amplification | 3 | 0.0 |
